Compare Starbucks Corp (SBUX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Starbucks Corp vs TG Therapeutics Inc — how do they compare? Starbucks Corp trades at $104.56 (market cap $119.45B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Starbucks Corp is far larger — about 14.5× TG Therapeutics Inc's market cap, and Starbucks Corp pays a 2.37% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SBUX | TGTX | |
|---|---|---|
Market Cap | $119.45B | $8.26B |
Volume | 7,493,833 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $108.37 | $59.06 |
52-Week Low | $78.46 | $26.39 |
Enterprise Value | $142.14B | $8.50B |
Dividend Yield | 2.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Starbucks (SBUX) trades at $104.45, down 0.99% today, near its 52-week high with a bullish technical trend. The company reported mixed quarterly earnings, beating Q1 2026 estimates but missing Q3 and Q4 2025. Revenue grew to $37.18B in 2025, though net income fell to $1.86B, reflecting margin pressures. Analysts maintain a buy consensus with a $108.86 target, citing turnaround progress and cost-saving initiatives, including AI-driven software reductions.
SBUX's outlook is cautiously optimistic, supported by traffic growth and raised 2026 guidance, but profitability remains a concern with a high P/E of 80.01. Key risks include intense competition from Luckin Coffee and macroeconomic sensitivity. Institutional sentiment is positive, with 47% buy ratings, though investors should monitor execution on margin recovery and cost efficiency targets.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
